Artrya Ltd (ASX:AYA)’s John Barrington discusses the company’s move into the US market, and its use of artificial intelligence in diagnosing early indicators for heart disease in clinical settings. The company is targeting heart disease as its main treatment focus, especially early indicators of disease that are currently under-utilised in diagnoses.
Artrya entered the US market with a US-based subsidiary of the same name just last month and has begun to fill out its management and clinical expertise as the company moves toward partnering and product design for the new market.